Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.5818
Abstract: Importance Myelofibrosis is a hematologic malignancy characterized by splenomegaly and debilitating symptoms. Thrombocytopenia is a poor prognostic feature and limits use of Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor ruxolitinib. Objective To compare the… read more here.
Keywords: patients patients; pacritinib; including ruxolitinib; bat ... See more keywords
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27418
Abstract: Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily aspirin… read more here.
Keywords: low dose; aspirin; daily low; twice daily ... See more keywords
Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI‐589 in Healthy Participants
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1146
Abstract: EPI‐589 attenuates oxidative stress due to the radical scavenging activity of the reduced form and affects mitochondrial energy metabolism as a substrate of quinone‐oxidoreductases. Given the effects of EPI‐589 on oxidative stress and mitochondrial dysfunction,… read more here.
Keywords: healthy participants; epi 589; twice daily; phase study ... See more keywords
A Bioequivalence Comparison Between the Once‐Daily Extended‐Release Tablet and the Twice‐Daily Tablet Formulations of Deutetrabenazine at Steady State
Sign Up to like & getrecommendations! Published in 2024 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1355
Abstract: Deutetrabenazine is approved for the treatment of tardive dyskinesia and chorea associated with Huntington's disease. This study compared the exposure between the once‐daily (test) and twice‐daily (reference) formulations of deutetrabenazine under fed conditions. Using a… read more here.
Keywords: tablet; formulations deutetrabenazine; twice daily; steady state ... See more keywords
Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.790
Abstract: Ursodeoxycholic acid (UDCA) is a secondary bile acid that is used to treat primary biliary cholangitis. Although UDCA has a hepatoprotective effect in some diseases, its benefit in nonalcoholic fatty liver disease (NAFLD) remains controversial.… read more here.
Keywords: liver function; udca 300; ursodeoxycholic acid; twice daily ... See more keywords
Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5‐Subtype Selective GABAA‐Positive Allosteric Modulator PF‐06372865 in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.912
Abstract: Multiple‐dose pharmacokinetics (PK) and safety were investigated in this phase 1 study of PF‐06372865, a positive allosteric modulator of α2/3/5 subunit‐containing γ‐aminobutyric acid A receptors (NCT03351751). In 2 cohorts (7‐8 PF‐06372865 and 2 placebo in… read more here.
Keywords: allosteric modulator; oral doses; safety; twice daily ... See more keywords
Is twice daily LF-rTMS a viable treatment option for treatment-resistant OCD? Results from an open-label feasibility study
Sign Up to like & getrecommendations! Published in 2020 at "European Archives of Psychiatry and Clinical Neuroscience"
DOI: 10.1007/s00406-020-01142-x
Abstract: Several reports point to the beneficial effects of repetitive transcranial magnetic stimulation (rTMS) in the treatment of resistant obsessive–compulsive disorder (OCD). This study aimed to evaluate the safety and efficacy of rTMS targeting the dmPFC… read more here.
Keywords: treatment resistant; treatment; twice daily; resistant ocd ... See more keywords
Experts’ Consensus on the Use of Pimecrolimus in Atopic Dermatitis in China: A TCS-Sparing Practical Approach
Sign Up to like & getrecommendations! Published in 2022 at "Dermatology and Therapy"
DOI: 10.1007/s13555-022-00696-z
Abstract: Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease with rising prevalence. Topical corticosteroids (TCS) are recommended as first-line therapy for patients with AD in China; however, corticophobia is a widespread concern, which can… read more here.
Keywords: pimecrolimus; twice daily; tcs; tcs sparing ... See more keywords
Understanding Perspectives on Presbyopia and Use of Pilocarpine HCl 1.25% Twice Daily from Participants of the Phase 3 VIRGO Study
Sign Up to like & getrecommendations! Published in 2024 at "Ophthalmology and Therapy"
DOI: 10.1007/s40123-024-00935-w
Abstract: The phase 3, randomized, vehicle-controlled, 14-day VIRGO study evaluated the efficacy and safety of twice-daily dosing of pilocarpine hydrochloride ophthalmic solution 1.25% (Pilo) in presbyopia. On VIRGO exit, a companion study was conducted to assess… read more here.
Keywords: pilo; vehicle; virgo study; twice daily ... See more keywords
Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0844-8
Abstract: Ticagrelor (Brilique®) is an orally administered P2Y12 inhibitor. A long-term (maintenance) regimen of ticagrelor 60 mg twice daily is indicated in the EU for coadministration with low-dose aspirin 75–150 mg/day for the secondary prevention of atherothrombotic events… read more here.
Keywords: ticagrelor; long term; twice daily; secondary prevention ... See more keywords
At-home telemedicine controlled taVNS twice daily for 4 weeks reduces long COVID symptoms of anxiety and fatigue
Sign Up to like & getrecommendations! Published in 2021 at "Brain Stimulation"
DOI: 10.1016/j.brs.2021.10.368
Abstract: s Brain Stimulation 14 (2021) 1589e1707 Carolina, Charleston, SC, USA; Ralph H Johnson VA Medical Center, read more here.
Keywords: tavns twice; twice daily; telemedicine controlled; controlled tavns ... See more keywords